CRBU Q4 2023 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-3.6% YoY

Gross Profit

$2M44.5% margin

Operating Income

-$37M-1052.3% margin

Net Income

-$35M-969.8% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-85.0%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$432M

Total Liabilities

$64M

Stockholders' Equity

$368M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	-3.6%
Gross Profit	$2M	-$22M	+107.2%
Operating Income	-$37M	-$31M	-22.4%
Net Income	-$35M	-$27M	-27.8%

Geographic Segments

UNITED STATES

$2M66%

Non-US

$1M34%